United States-based Pfizer has agreed to integrate its off-patent branded and generic established medicines business Upjohn with Mylan to set up a new global pharmaceutical company, it was reported yesterday.
Based on an all-stock Reverse Morris Trust transaction, each share of Mylan will be converted into one share of the new company. The transaction enables Pfizer shareholders to own a 57% share in the new company, while Mylan shareholders will own the remaining 43% interest.
The new company is to serve more than 165 markets and will have a diverse portfolio that covers major therapeutic areas such as central nervous system and anaesthesia, infectious disease and cardiovascular. It will have a diverse and differentiated portfolio of prescription medicines, complex generics, over-the-counter products and biosimilars. The new company is expected to have pro forma 2020 revenues between USD19bn and USD20bn and the pro forma adjusted EBITDA between USD7.5bn and USD8bn for the same period. The deal is likely to be completed in mid-2020 subject to approval by Mylan shareholders and customary closing conditions.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling